TY  - RPRT
TI  - Bevacizumab in the treatment of ovarian cancer
AU  - Neyt Mattias
AU  - Devriese Stephan
AU  - Camberlin Cécile
AU  - Vlayen Joan
AB  - KCE Reports 285C (2017)

Bevacizumab (Avastin®) is a drug used in combination with chemotherapy in ovarian cancer. It keeps the tumor under control for longer, but because of its serious side effects, it decreases the overall quality of life (short-term) of most patients … without it being possible to prove that it increases their total survival.
T2  - KCE Reports
CY  - Brussel
PY  - 2017
LA  - English
M3  - Health Technology Assessment (HTA)
PB  - Belgian Health Care Knowledge Centre (KCE)
SN  - 285
VO  - D/2017/10.273/23
DO  - http://doi.org/10.57598/R285C
ER -